156 related articles for article (PubMed ID: 34224206)
21. Enzymatic and Inhibition Mechanism of Human Aromatase (CYP19A1) Enzyme. A Computational Perspective from QM/MM and Classical Molecular Dynamics Simulations.
Sgrignani J; Cavalli A; Colombo G; Magistrato A
Mini Rev Med Chem; 2016; 16(14):1112-24. PubMed ID: 27337972
[TBL] [Abstract][Full Text] [Related]
22. New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.
Stauffer F; Furet P; Floersheimer A; Lang M
Bioorg Med Chem Lett; 2012 Mar; 22(5):1860-3. PubMed ID: 22335894
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H.
Parween S; DiNardo G; Baj F; Zhang C; Gilardi G; Pandey AV
J Steroid Biochem Mol Biol; 2020 Feb; 196():105507. PubMed ID: 31669572
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of α-methylstilbenes using an aqueous Wittig methodology and application toward the development of potent human aromatase inhibitors.
Nielsen AJ; Raez-Villanueva S; Crankshaw DJ; Holloway AC; McNulty J
Bioorg Med Chem Lett; 2019 Jun; 29(11):1395-1398. PubMed ID: 30952594
[TBL] [Abstract][Full Text] [Related]
25. Exploration of structural requirements for azole chemicals towards human aromatase CYP19A1 activity: Classification modeling, structure-activity relationships and read-across study.
Caballero Alfonso AY; Mora Lagares L; Novic M; Benfenati E; Kumar A; Chayawan
Toxicol In Vitro; 2022 Jun; 81():105332. PubMed ID: 35176449
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, in vitro and in silico studies of some novel thiazole-dihydrofuran derivatives as aromatase inhibitors.
Osmaniye D; Görgülü Ş; Sağlık BN; Levent S; Özkay Y; Kaplancıklı ZA
Bioorg Chem; 2021 Sep; 114():105123. PubMed ID: 34214753
[TBL] [Abstract][Full Text] [Related]
27. Lead optimization of 4-imidazolylflavans: new promising aromatase inhibitors.
Yahiaoui S; Pouget C; Buxeraud J; Chulia AJ; Fagnère C
Eur J Med Chem; 2011 Jun; 46(6):2541-5. PubMed ID: 21497425
[TBL] [Abstract][Full Text] [Related]
28. Effects of new C6-substituted steroidal aromatase inhibitors in hormone-sensitive breast cancer cells: Cell death mechanisms and modulation of estrogen and androgen receptors.
Augusto TV; Amaral C; Varela CL; Bernardo F; da Silva ET; Roleira FFM; Costa S; Teixeira N; Correia-da-Silva G
J Steroid Biochem Mol Biol; 2019 Dec; 195():105486. PubMed ID: 31557516
[TBL] [Abstract][Full Text] [Related]
29. Aromatase Inhibitors for the Treatment of Breast Cancer: A Journey from the Scratch.
Ratre P; Mishra K; Dubey A; Vyas A; Jain A; Thareja S
Anticancer Agents Med Chem; 2020; 20(17):1994-2004. PubMed ID: 32593281
[TBL] [Abstract][Full Text] [Related]
30. Combating breast cancer with non-steroidal aromatase inhibitors (NSAIs): Understanding the chemico-biological interactions through comparative SAR/QSAR study.
Adhikari N; Amin SA; Saha A; Jha T
Eur J Med Chem; 2017 Sep; 137():365-438. PubMed ID: 28622580
[TBL] [Abstract][Full Text] [Related]
31. Effects of Folpet, Captan, and Captafol on Human Aromatase in JEG-3 Cells.
Ge H; Chen L; Su Y; Jin C; Ge RS
Pharmacology; 2018; 102(1-2):81-87. PubMed ID: 29953993
[TBL] [Abstract][Full Text] [Related]
32. Design, Synthesis, and Biological Evaluation of New Azole Derivatives as Potent Aromatase Inhibitors with Potential Effects against Breast Cancer.
Kalalinia F; Jouya M; Komachali AK; Aboutourabzadeh SM; Karimi G; Behravan J; Abnous K; Etemad L; Kamali H; Hadizadeh F
Anticancer Agents Med Chem; 2018; 18(7):1016-1024. PubMed ID: 29336269
[TBL] [Abstract][Full Text] [Related]
33. Aromatase inhibitors: Role in postmenopausal breast cancer.
Kharb R; Haider K; Neha K; Yar MS
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000081. PubMed ID: 32449548
[TBL] [Abstract][Full Text] [Related]
34. A review on diverse heterocyclic compounds as the privileged scaffolds in non-steroidal aromatase inhibitors.
Rani S; Raheja K; Luxami V; Paul K
Bioorg Chem; 2021 Aug; 113():105017. PubMed ID: 34091288
[TBL] [Abstract][Full Text] [Related]
35. Direct spectroscopic evidence for binding of anastrozole to the iron heme of human aromatase. Peering into the mechanism of aromatase inhibition.
Maurelli S; Chiesa M; Giamello E; Di Nardo G; Ferrero VE; Gilardi G; Van Doorslaer S
Chem Commun (Camb); 2011 Oct; 47(38):10737-9. PubMed ID: 21858332
[TBL] [Abstract][Full Text] [Related]
36. Preclinical pharmacological evaluation of letrozole as a novel treatment for gliomas.
Dave N; Chow LM; Gudelsky GA; LaSance K; Qi X; Desai PB
Mol Cancer Ther; 2015 Apr; 14(4):857-64. PubMed ID: 25695958
[TBL] [Abstract][Full Text] [Related]
37. Aromatase inhibitor exemestane has antiproliferative effects on human mesothelioma cells.
Stoppoloni D; Salvatori L; Biroccio A; D'Angelo C; Muti P; Verdina A; Sacchi A; Vincenzi B; Baldi A; Galati R
J Thorac Oncol; 2011 Mar; 6(3):583-91. PubMed ID: 21289517
[TBL] [Abstract][Full Text] [Related]
38. Aromatase: the enzyme and its inhibition.
Banting L; Ahmed S
Anticancer Agents Med Chem; 2009 Jul; 9(6):627-41. PubMed ID: 19601746
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19).
Lu DF; Yang LJ; Wang F; Zhang GL
J Agric Food Chem; 2012 Aug; 60(34):8411-8. PubMed ID: 22838964
[TBL] [Abstract][Full Text] [Related]
40. An efficient steroid pharmacophore-based strategy to identify new aromatase inhibitors.
Neves MA; Dinis TC; Colombo G; Sá e Melo ML
Eur J Med Chem; 2009 Oct; 44(10):4121-7. PubMed ID: 19500885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
